CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Seattle Genetics, Inc. - SGEN CFD

212.14
0.03%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Seagen Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 212.07
Open* 212.6
1-Year Change* 54.45%
Day's Range* 212.03 - 213.17
52 wk Range 116.08-210.50
Average Volume (10 days) 1.70M
Average Volume (3 months) 24.05M
Market Cap 38.46B
P/E Ratio -100.00K
Shares Outstanding 187.70M
Revenue 2.16B
EPS -3.89
Dividend (Yield %) N/A
Beta 0.48
Next Earnings Date Oct 25, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 212.14 0.27 0.13% 211.87 213.41 211.70
Sep 28, 2023 212.07 -0.35 -0.16% 212.42 212.75 211.54
Sep 27, 2023 212.31 -2.12 -0.99% 214.43 214.76 212.13
Sep 26, 2023 215.91 0.76 0.35% 215.15 216.97 215.13
Sep 25, 2023 215.40 2.35 1.10% 213.05 215.63 213.05
Sep 22, 2023 213.56 -0.19 -0.09% 213.75 213.93 212.95
Sep 21, 2023 206.31 0.57 0.28% 205.74 207.45 205.29
Sep 20, 2023 206.96 -0.26 -0.13% 207.22 208.18 206.42
Sep 19, 2023 208.05 1.49 0.72% 206.56 208.58 206.19
Sep 18, 2023 207.12 0.26 0.13% 206.86 208.09 206.70
Sep 15, 2023 208.24 2.03 0.98% 206.21 208.34 204.95
Sep 14, 2023 206.35 0.45 0.22% 205.90 207.06 205.87
Sep 13, 2023 205.82 0.87 0.42% 204.95 207.42 204.95
Sep 12, 2023 207.30 0.96 0.47% 206.34 207.87 206.23
Sep 11, 2023 208.01 3.86 1.89% 204.15 208.37 203.10
Sep 8, 2023 204.36 0.06 0.03% 204.30 205.23 203.46
Sep 7, 2023 204.78 -0.47 -0.23% 205.25 206.15 204.67
Sep 6, 2023 205.91 -0.82 -0.40% 206.73 207.25 205.48
Sep 5, 2023 207.04 -0.69 -0.33% 207.73 208.03 206.81
Sep 1, 2023 207.76 -2.17 -1.03% 209.93 210.32 207.39

Seattle Genetics, Inc. Events

Time (UTC) Country Event
Wednesday, October 25, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Seagen Inc Earnings Release
Q3 2023 Seagen Inc Earnings Release

Forecast

-

Previous

-
Tuesday, February 13, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Seagen Inc Earnings Release
Q4 2023 Seagen Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1962.41 1574.37 2175.54 916.713 654.7
Revenue 1962.41 1574.37 2175.54 916.713 654.7
Cost of Revenue, Total 410.058 311.565 217.72 43.952 88.293
Gross Profit 1552.35 1262.81 1957.82 872.761 566.407
Total Operating Expense 2575.38 2256.43 1578.68 1137.26 914.698
Selling/General/Admin. Expenses, Total 820.963 716.19 533.835 373.932 252.596
Research & Development 1344.36 1228.67 827.129 719.374 565.309
Operating Income -612.97 -682.056 596.852 -220.545 -259.998
Interest Income (Expense), Net Non-Operating 10.655 6.351 18.849 61.895 13.652
Net Income Before Taxes -602.315 -675.705 615.701 -158.65 -246.346
Net Income After Taxes -610.308 -674.471 613.67 -158.65 -222.693
Net Income Before Extra. Items -610.308 -674.471 613.67 -158.65 -222.693
Net Income -610.308 -674.471 613.67 -158.65 -222.693
Income Available to Common Excl. Extra. Items -610.308 -674.471 613.67 -158.65 -222.693
Income Available to Common Incl. Extra. Items -610.308 -674.471 613.67 -158.65 -222.693
Diluted Net Income -610.308 -674.471 613.67 -158.65 -222.693
Diluted Weighted Average Shares 184.676 182.048 182.287 165.498 157.655
Diluted EPS Excluding Extraordinary Items -3.30475 -3.70491 3.3665 -0.95862 -1.41253
Diluted Normalized EPS -3.30475 -3.70491 3.3665 -0.95862 -1.37749
Total Extraordinary Items 0
Unusual Expense (Income) 8.5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 603.832 519.719 528.15 510.3 497.502
Revenue 603.832 519.719 528.15 510.3 497.502
Cost of Revenue, Total 180.753 111.776 108.21 108.122 106.1
Gross Profit 423.079 407.943 419.94 402.178 391.402
Total Operating Expense 824.553 704.232 682.154 703.105 630.613
Selling/General/Admin. Expenses, Total 236.932 206.441 216.101 210.378 220.259
Research & Development 399.868 356.015 357.843 384.605 304.254
Operating Income -220.721 -184.513 -154.004 -192.805 -133.111
Interest Income (Expense), Net Non-Operating 12.084 14.4 10.176 4.278 -1.609
Net Income Before Taxes -208.637 -170.113 -143.828 -188.527 -134.72
Net Income After Taxes -211.528 -174.737 -148.171 -190.816 -134.827
Net Income Before Extra. Items -211.528 -174.737 -148.171 -190.816 -134.827
Net Income -211.528 -174.737 -148.171 -190.816 -134.827
Income Available to Common Excl. Extra. Items -211.528 -174.737 -148.171 -190.816 -134.827
Income Available to Common Incl. Extra. Items -211.528 -174.737 -148.171 -190.816 -134.827
Diluted Net Income -211.528 -174.737 -148.171 -190.816 -134.827
Diluted Weighted Average Shares 187.559 186.889 186.107 184.792 184.145
Diluted EPS Excluding Extraordinary Items -1.12779 -0.93498 -0.79616 -1.0326 -0.73218
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.10354 -0.83064 -0.79616 -1.0326 -0.73218
Unusual Expense (Income) 7 30
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2802.53 2869.19 3062.38 1176.64 653.595
Cash and Short Term Investments 1735.07 2160.04 2559.42 811.055 410.672
Cash & Equivalents 319.94 424.834 558.424 274.562 78.186
Short Term Investments 1415.13 1735.2 2001 536.493 332.486
Total Receivables, Net 501.912 389.256 324.988 236.001 146.281
Accounts Receivable - Trade, Net 501.912 389.256 324.988 236.001 146.281
Total Inventory 427.211 200.663 116.136 85.932 53.239
Prepaid Expenses 134.794 119.239 61.84 43.653 43.403
Total Assets 3674.53 3719.6 4000.91 2205.87 1503.33
Property/Plant/Equipment, Total - Net 294.917 267.962 258.18 220.721 103.82
Property/Plant/Equipment, Total - Gross 551.67 480.444 434.2 365.086 225.004
Accumulated Depreciation, Total -256.753 -212.482 -176.02 -144.365 -121.184
Intangibles, Net 237.516 260.593 283.68 300 300.04
Long Term Investments 0 100.83 57.283 49.194
Other Long Term Assets, Total 64.895 47.184 21.161 176.55 122.009
Total Current Liabilities 818.404 568.854 388.138 259.357 225.072
Accounts Payable 207.851 114.824 78.067 52.292 44.179
Accrued Expenses 610.553 454.03 279.941 207.065 147.293
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 30.13 0 33.6
Total Liabilities 870.713 654.465 512.806 329.579 229.386
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 52.309 85.611 124.668 70.222 4.314
Total Equity 2803.82 3065.14 3488.1 1876.29 1273.94
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.187 0.183 0.181 0.172 0.16
Additional Paid-In Capital 4954.47 4607.82 4356.92 3359.12 2598.41
Retained Earnings (Accumulated Deficit) -2154.35 -1544.04 -869.568 -1483.24 -1324.59
Other Equity, Total 3.51 1.179 0.565 0.229 -0.04
Total Liabilities & Shareholders’ Equity 3674.53 3719.6 4000.91 2205.87 1503.33
Total Common Shares Outstanding 186.559 183.381 180.902 171.994 160.262
Goodwill, Net 274.671 274.671 274.671 274.671 274.671
Other Current Assets, Total 3.546
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 2601.91 2802.53 2759.62 2778.66 2771.25
Cash and Short Term Investments 1490.27 1735.07 1763.7 1850.32 1951.09
Cash & Equivalents 335.847 319.94 362.601 364.874 260.996
Short Term Investments 1154.43 1415.13 1401.1 1485.45 1690.1
Total Receivables, Net 495.777 501.912 486.755 438.041 401.009
Accounts Receivable - Trade, Net 495.777 501.912 486.755 438.041 401.009
Total Inventory 477.694 427.211 364.97 319.354 275.747
Prepaid Expenses 136.979 134.794 138.423 170.938 143.406
Total Assets 3543.3 3674.53 3619.08 3630.34 3616.69
Property/Plant/Equipment, Total - Net 378.957 294.917 279.61 270.843 269.316
Goodwill, Net 274.671 274.671 274.671 274.671 274.671
Intangibles, Net 231.826 237.516 243.332 249.149 254.902
Long Term Investments
Other Long Term Assets, Total 55.931 64.895 61.846 57.025 46.549
Total Current Liabilities 713.228 818.404 725.998 608.521 531.294
Accounts Payable 141.475 207.851 144.499 128.872 87.228
Accrued Expenses 571.753 610.553 581.499 479.649 444.066
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 820.14 870.713 797.267 697.531 618.226
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 106.912 52.309 71.269 89.01 86.932
Total Equity 2723.16 2803.82 2821.81 2932.81 2998.47
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.187 0.187 0.185 0.184 0.184
Additional Paid-In Capital 5048.35 4954.47 4824.81 4747.48 4678.39
Retained Earnings (Accumulated Deficit) -2329.08 -2154.35 -2006.18 -1815.36 -1680.53
Other Equity, Total 3.708 3.51 2.995 0.507 0.424
Total Liabilities & Shareholders’ Equity 3543.3 3674.53 3619.08 3630.34 3616.69
Total Common Shares Outstanding 187.289 186.559 185.234 184.369 183.892
Other Current Assets, Total 1.189 3.546 5.769
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -610.308 -674.471 613.67 -158.65 -222.693
Cash From Operating Activities -453.751 -499.007 856.568 -163.737 -203.536
Cash From Operating Activities 46.727 42.854 36.045 23.774 26.032
Non-Cash Items 236.74 196.991 149.701 83.902 70.676
Changes in Working Capital -150.54 -88.016 42.86 -112.763 -53.898
Cash From Investing Activities 228.237 288.884 -1419.01 -277.729 -592.63
Capital Expenditures -77.34 -52.33 -82.409 -70.753 -21.219
Other Investing Cash Flow Items, Total 305.577 341.214 -1336.6 -206.976 -571.411
Cash From Financing Activities 125.36 77.779 846.108 637.842 713.407
Issuance (Retirement) of Stock, Net 125.36 77.779 846.108 637.842 713.407
Net Change in Cash -101.348 -133.59 283.862 196.376 -82.759
Deferred Taxes 0.553 0.548 -2.053 0 -23.653
Amortization 23.077 23.087 16.345
Foreign Exchange Effects -1.194 -1.246 0.198
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -174.737 -610.308 -462.137 -271.321 -136.494
Cash From Operating Activities -249.643 -453.751 -374.311 -288.582 -216.812
Cash From Operating Activities 12.423 46.727 34.642 22.867 11.402
Amortization 5.69 23.077 17.261 11.444 5.691
Non-Cash Items 56.881 236.74 175.039 111.744 49.828
Changes in Working Capital -150.111 -150.54 -138.895 -162.759 -147.394
Cash From Investing Activities 232.336 228.237 264.727 199.756 26.663
Capital Expenditures -38.655 -77.34 -48.095 -32.161 -17.397
Other Investing Cash Flow Items, Total 270.991 305.577 312.822 231.917 44.06
Cash From Financing Activities 29.937 125.36 60.013 41.624 26.664
Issuance (Retirement) of Stock, Net 42.24 125.36 60.013 41.624 26.664
Foreign Exchange Effects 0.92 -1.194 -6.893 -2.809 -0.353
Net Change in Cash 13.55 -101.348 -56.464 -50.011 -163.838
Deferred Taxes 0.211 0.553 -0.221 -0.557 0.155
Financing Cash Flow Items -12.303
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Baker Bros. Advisors LP Hedge Fund 23.7372 44554162 -4088 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.0615 13254362 152154 2023-06-30 LOW
Pentwater Capital Management LP Hedge Fund 5.1303 9629500 7874500 2023-06-30 HIGH
Capital World Investors Investment Advisor 4.8383 9081409 -3188031 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.4223 8300626 477794 2023-06-30 LOW
Capital International Investors Investment Advisor 3.4189 6417224 -810641 2023-06-30 LOW
PRIMECAP Management Company Investment Advisor 3.2173 6038808 1144000 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.7764 3334204 -20028 2023-06-30 LOW
Invesco Capital Management (QQQ Trust) Investment Advisor 1.699 3188968 677696 2023-07-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.2007 2253733 -4575730 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.1652 2187105 473466 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.0984 2061760 87737 2023-06-30 LOW
Barclays Bank PLC Investment Advisor 1.0279 1929326 1775088 2023-06-30 MED
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 0.9375 1759606 -42300 2023-06-30 LOW
Millennium Management LLC Hedge Fund 0.8703 1633535 893994 2023-06-30 HIGH
JP Morgan Asset Management Investment Advisor 0.8545 1603838 -765853 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.701 1315820 -117574 2023-06-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.5989 1124091 250655 2023-06-30 LOW
DWS Investments UK Limited Investment Advisor 0.4813 903451 720565 2023-06-30 MED
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.4722 886400 77328 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Seattle Company profile

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry: Biotechnology & Medical Research (NEC)

21823 30Th Drive Se
Suite
BOTHELL
WASHINGTON 98021
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

ETH/USD

1,672.82 Price
+0.150% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Oil - Crude

90.04 Price
-1.230% 1D Chg, %
Long position overnight fee 0.0661%
Short position overnight fee -0.0881%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
-3.290% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

26,970.35 Price
+0.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading